Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allisartan medoxomil + amlodipine fixed-dose combination in essential hypertension uncontrolled on monotherapy
ChiCTR2100050666Phase 3Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of allisartan medoxomil and amlodipine in essential hypertension (4 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Change in mean sitting systolic blood pressure from baseline. Started Sep 2021; status: recruiting.
02
Drugs
allisartan medoxomilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2100050666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050666.